Today, Horizon Pharma’s (HZNP) “Outperform” Rating Reaffirm at BMO Capital Markets

Today, Horizon Pharma’s (HZNP) “Outperform” Rating Reaffirm at BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a research report report published on Monday morning. BMO Capital Markets currently has a $29.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the company. Citigroup Inc. raised Horizon Pharma from a neutral rating to a buy rating in a report on Monday. Mizuho boosted their price target on Horizon Pharma from $29.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, November 8th. Goldman Sachs Group Inc. set a $26.00 price target on Horizon Pharma and gave the stock a buy rating in a report on Wednesday, October 12th. Vetr raised Horizon Pharma from a buy rating to a strong-buy rating in a report on Monday, October 3rd. Finally, Morgan Stanley reaffirmed a hold rating and set a $24.00 price objective on shares of Horizon Pharma in a report on Wednesday, September 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $29.62.

Horizon Pharma (NASDAQ:HZNP) opened at 21.18 on Monday. Horizon Pharma has a one year low of $13.05 and a one year high of $23.44. The company’s market cap is $3.42 billion. The stock has a 50 day moving average of $18.75 and a 200 day moving average of $18.60.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.07. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. The company had revenue of $273.70 million for the quarter, compared to analysts’ expectations of $270.04 million. During the same period in the previous year, the firm earned $0.70 EPS. The firm’s revenue was up 20.8% compared to the same quarter last year. On average, analysts anticipate that Horizon Pharma will post $2.02 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in Horizon Pharma during the third quarter worth $112,000. Societe Generale acquired a new stake in Horizon Pharma during the second quarter worth $117,000. SG Americas Securities LLC acquired a new stake in Horizon Pharma during the second quarter worth $117,000. Nuveen Asset Management LLC acquired a new stake in Horizon Pharma during the second quarter worth $176,000. Finally, Profund Advisors LLC acquired a new stake in Horizon Pharma during the second quarter worth $194,000. Institutional investors and hedge funds own 86.91% of the company’s stock.

About Horizon Pharma

Related posts

Leave a Comment